Hikma Pharmaceuticals Stock
Pros and Cons of Hikma Pharmaceuticals in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
S********** s********
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Hikma Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Hikma Pharmaceuticals | 0.100% | 5.234% | 3.264% | -4.455% | 9.659% | -23.413% | -33.448% |
| Viatris Inc. | -0.180% | -7.902% | -1.025% | 69.170% | 33.859% | 38.799% | 9.335% |
| Repligen Corp. | -0.780% | 10.642% | 11.911% | 47.784% | 0.390% | -9.936% | -33.801% |
| Opko Health Inc. | 3.480% | 0.885% | 0.000% | 11.328% | 4.568% | -28.679% | -63.415% |
Comments
Hikma Pharmaceuticals (OTCMKTS:HKMPF) was downgraded by analysts at Barclays PLC to an "underweight" rating.
Show more
Ratings data for HKMPF provided by MarketBeat
Hikma Pharmaceuticals PLC (OTCMKTS: HKMPF) is now covered by analysts at BNP Paribas. They set an "outperform" rating on the stock.
Show more
Ratings data for HKMPF provided by MarketBeat
